Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PTCT
PTCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PTCT News
PTC Therapeutics Withdraws New Drug Application for Translarna
2d ago
Benzinga
PTC Therapeutics Withdraws NDA Resubmission for Translarna
3d ago
seekingalpha
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
3d ago
PRnewswire
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
3d ago
Newsfilter
Rare Disease Biotechs Show Strong 2025 Performance with Cashflow and R&D Expansion
Jan 14 2026
Yahoo Finance
PTC Therapeutics Launches Sephience™ with Q4 Revenue of $92.5M
Jan 12 2026
PRnewswire
PTC Therapeutics Grants 300 RSUs to Attract New Employee
Jan 08 2026
Newsfilter
PTC Therapeutics Grants 300 RSUs to Attract New Employee
Jan 08 2026
PRnewswire
Royalty Pharma Acquires Evrysdi Royalty for $240 Million Upfront
Dec 31 2025
Benzinga
Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
Dec 31 2025
Barron's
Royalty Pharma Acquires Remaining Evrysdi Royalty Interest for $240M Upfront
Dec 30 2025
NASDAQ.COM
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
PTC Therapeutics Receives Approval for Sephience in Japan for PKU Treatment
Dec 22 2025
PRnewswire
PTC Therapeutics Secures Approval for Sephience in Japan for PKU Treatment
Dec 22 2025
Newsfilter
PTC Therapeutics Grants Stock Options and RSUs to New Employees
Dec 19 2025
PRnewswire
PTC Therapeutics CEO to Present at 44th J.P. Morgan Healthcare Conference
Dec 18 2025
PRnewswire
Show More News
